NFKB1 and hematocrit: Since levothyroxine replacement therapy does not reduce NF-kB expression or increase circulating levels of anti-inflammatory molecules such as Maresin 1, we can assume that it does not have a net effect on pro- and anti-inflammatory balance in HT patients.